CERo Therapeutics Presents CER-1236 Clinical Data at ASTCT Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy ?
Source: Newsfilter
- Clinical Trial Progress: CERo Therapeutics presented data from its Phase 1 clinical trial of CER-1236 at the ASTCT meeting, demonstrating a 20-70 fold cell expansion, indicating the potential efficacy and safety of this therapy in acute myeloid leukemia (AML) patients.
- Significant Patient Outcomes: An AML patient achieved over two months of transfusion independence after four infusions of CER-1236, exceeding the commonly used ≥56-day durability benchmark, showcasing the clinical applicability of this therapy.
- Good Safety Profile: No dose-limiting toxicities or cytokine release syndrome (CRS) were observed in the first four treated patients, supporting further clinical evaluation of CER-1236 in myeloid disease settings.
- Study Expansion Plans: CERo has amended the trial protocol to include transfusion-dependent myelodysplastic syndromes (TD-MDS), highlighting the broad potential across multiple tumor types and advancing the clinical trial's progress.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
